**Supplementary Table S1. Exploratory efficacy analysis (per-protocol population)**

|  |  |  |
| --- | --- | --- |
| **Efficacy Outcomes** | **Arm A**  **(N = 48)** | **Arm B (N = 23)** |
| Median PFS (months) (90% CI)a | 2.0 (1.9, 3.7) | 1.9 (1.8, 4.3) |
| 6-month PFS rate, %, (90% CI)a | 20.1 (10.4, 32.1) | 18.2 (7.2, 33.2) |
| 1-year PFS rate, %, (90% CI)a | 16.8 (7.9, 28.5) | 9.1 (2.2, 22.1) |
| 2-year PFS rate, %, (90% CI)a | 4.2 (0.6, 14.4) | NR |
| Best overall response, n (%) |  |  |
| Complete response (CR) | 0 (0.0) | 0 (0.0) |
| Partial response (PR) | 0 (0.0) | 0 (0.0) |
| Stable disease (SD) | 19 (39.6) | 10 (43.5) |
| Progressive disease | 26 (54.2) | 13 (56.5) |
| Not evaluable/available | 3 (6.3) | 0 (0.0) |
| Objective response rate (CR+PR), % (95% CI)b | 0 (0.0, 7.4) | 0 (0.0, 14.8) |
| Disease control (CR+PR+SD), % (95% CI)b | 39.6 (25.8, 54.7) | 43.5 (23.2, 65.5) |
| Median OS (months) (90% CI)a | 20.3 (11.5, NR) | NR (17.8, NR) |
| 6-month OS rate, % (90% CI)a | 76.2 (63.9, 84.7) | 95.7 (79.4, 99.1) |
| 1-year OS rate, % (90% CI)a | 64.5 (51.4, 74.9) | 77.8 (59.1, 88.7) |
| 2-year OS rate, % (90% CI)a | 46.4 (26.1, 64.5) | 51.9 (24.0, 73.9) |

Abbreviations: Arm A = cixutumumab + anti-estrogen; Arm B = cixutumumab; CI = confidence interval; N = number of patients for each treatment; n = number of patients per category for each treatment; NR = not reached; OS = overall survival; PFS = progression-free survival.

aEstimated by Kaplan-Meier method.

bEstimated using binomial distribution.